Natco Pharma Expects India’s First CL Use To Add 15% To Sales Next Year
This article was originally published in PharmAsia News
Executive Summary
India’s Natco Pharma Ltd., which won a precedent-setting compulsory license for a generic of a foreign-made drug, expects a 15% increase in next year’s fiscal year, primarily because of the license.